D. N. Louis, A. Perry, and G. Reifenberger, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

M. Weller, M. Van-den-bent, and K. Hopkins, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, The Lancet Oncology, 2014.

R. Soffietti, B. G. Baumert, and L. Bello, Guidelines on management of lowgrade gliomas: report of an EFNS-EANO Task Force, Eur J Neurol, vol.17, issue.9, 2010.

T. Rice, D. H. Lachance, and A. M. Molinaro, Understanding inherited genetic risk of adult glioma -a review, Neurooncol Pract, vol.3, issue.1, pp.10-16, 2016.

L. Douw, M. Klein, and S. S. Fagel, Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up, Lancet Neurol, vol.8, issue.9, pp.810-818, 2009.

M. J. Taphoorn, R. Henriksson, and A. Bottomley, Health-related quality of life in

, Acta Neuropathol, vol.128, issue.4, pp.551-560, 2014.

U. Herrlinger, D. T. Jones, and M. Glas, Gliomatosis cerebri: no evidence for a separate brain tumor entity, Acta Neuropathol, vol.131, issue.2, pp.309-328, 2016.

M. Weller, S. M. Pfister, W. Wick, M. E. Hegi, G. Reifenberger et al., Molecular neuro-oncology in clinical practice: a new horizon, The Lancet Oncology, vol.14, issue.9, pp.370-379, 2013.

W. Stummer, U. Pichlmeier, and T. Meinel, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, The Lancet Oncology, vol.7, issue.5, pp.392-401, 2006.

M. Osswald, E. Jung, and F. Sahm, Brain tumour cells interconnect to a functional and resistant network, Nature, vol.528, issue.7580, pp.93-101, 2015.

M. A. Vogelbaum, S. Jost, and M. K. Aghi, Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group, Neurosurgery, vol.70, issue.1, pp.234-277, 2012.

N. Laperriere, L. Zuraw, and G. Cairncross, Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site G. Radiotherapy for newly diagnosed 33

V. Vuorinen, S. Hinkka, M. Farkkila, and J. Jaaskelainen, Debulking or biopsy of malignant glioma in elderly people -a randomised study, Acta Neurochir (Wien), vol.145, issue.1, pp.5-10, 2003.

F. W. Kreth, N. Thon, and M. Simon, Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy, Ann Oncol, 2013.

T. Asklund, A. Malmstrom, M. Bergqvist, O. Bjor, and R. Henriksson, Brain tumors in Sweden: data from a population-based registry 1999-2012, Acta Oncol, vol.54, issue.3, pp.377-84, 2015.

M. D. Walker, E. Alexander, J. Hunt, and W. E. , Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, vol.49, issue.3, pp.333-376, 1978.

F. Keime-guibert, O. Chinot, and L. Taillandier, Radiotherapy for glioblastoma in the elderly, N Engl J Med, vol.356, issue.15, pp.1527-1562, 2007.

W. Roa, P. M. Brasher, and G. Bauman, Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.10, issue.5, pp.459-66, 2009.

M. G. Hart, R. Garside, G. Rogers, K. Stein, and R. Grant, Temozolomide for high grade glioma, Cochrane Database Syst Rev, issue.4, p.7415, 2013.

M. E. Hegi, A. C. Diserens, and T. Gorlia, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, vol.352, issue.10, pp.997-1003, 2005.

M. Weller, R. Stupp, and G. Reifenberger, MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nature reviews Neurology, vol.6, issue.1, pp.39-51, 2010.

W. Wick, M. Weller, and M. Van-den-bent, MGMT testing--the challenges for biomarker-based glioma treatment, Nature reviews Neurology, vol.10, issue.7, pp.372-85, 2014.

M. E. Hegi and R. Stupp, Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?, Neuro Oncol, vol.17, issue.11, pp.1425-1432, 2015.

M. R. Gilbert, M. Wang, and K. D. Aldape, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.31, issue.32, pp.4085-91, 2013.

D. Blumenthal, R. Stupp, and P. Zhang, The impact of extended adjuvant discussion, Acta Neurochir (Wien), vol.153, issue.6, pp.1211-1219, 2011.

M. R. Gilbert, J. J. Dignam, and T. S. Armstrong, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, vol.370, issue.8, pp.699-708, 2014.

O. L. Chinot, W. Wick, and W. Mason, Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma, N Engl J Med, vol.370, issue.8, pp.709-731, 2014.

R. Stupp, S. Taillibert, and A. A. Kanner, Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial, JAMA, vol.314, issue.23, pp.2535-2578, 2015.

W. Wick, TTFields: where does all the skepticism come from?, Neuro Oncol, vol.18, issue.3, pp.303-308, 2016.

F. Bernard-arnoux, M. Lamure, F. Ducray, G. Aulagner, J. Honnorat et al., The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma, Neuro Oncol, vol.18, issue.8, pp.1129-1165, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01804521

B. Suchorska, M. Weller, and G. Tabatabai, Complete resection of contrastenhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial, Neuro Oncol, vol.18, issue.4, pp.549-56, 2016.

, cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors, J Neurooncol, vol.116, issue.1, pp.161-169, 2014.

M. C. Chamberlain and S. Johnston, Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma, Cancer, vol.115, issue.8, pp.1734-1777, 2009.

S. Taillibert, L. A. Vincent, and B. Granger, Bevacizumab and irinotecan for recurrent oligodendroglial tumors, Neurology, vol.72, issue.18, pp.1601-1607, 2009.

D. N. Franz, K. Agricola, and M. Mays, Everolimus for subependymal giant cell astrocytoma: 5-year final analysis, Ann Neurol, vol.78, issue.6, pp.929-967, 2015.

M. C. Chamberlain, Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series, J Neurooncol, 2013.

M. Brainin, M. Barnes, and J. C. Baron, Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations, Eur J Neurol, vol.11, issue.9, pp.577-81, 2004.